AP-7 (drug)

From Wikipedia, the free encyclopedia
(Redirected from AP7 (drug))
Jump to navigation Jump to search

<templatestyles src="Chembox/styles.css"/>

Template:Chembox image cellTemplate:Chembox AllOtherNamesTemplate:Chembox headerbarTemplate:Chembox IndexlistTemplate:Chembox JmolTemplate:Chembox ChEMBLTemplate:Chembox ECHATemplate:Chembox E numberTemplate:Chembox IUPHAR ligandTemplate:Chembox UNIITemplate:Chembox CompToxTemplate:Chembox headerbarTemplate:Chembox HazardsTemplate:Chembox Datapage checkTemplate:Yesno
AP-7
Template:Longitem Template:Unbulleted list
ChEBI Template:Unbulleted list
ChemSpider Template:Unbulleted list
DrugBank Template:Unbulleted list
EC Number Template:Unbulleted list
KEGG Template:Unbulleted list
Template:Longitem Template:Unbulleted list
RTECS number Template:Unbulleted list
Script error: No such module "collapsible list".
Script error: No such module "collapsible list".
Template:Longitem C7H16NO5P
Molar mass 225.179 g/mol
Density 1.39 g/mL
Boiling point Template:Chembox CalcTemperatures

Template:Chembox Footer/tracking container onlyScript error: No such module "TemplatePar".Template:Short description

AP-7 is a selective NMDA receptor (NMDAR) antagonist that competitively inhibits the glutamate binding site and thus activation of NMDAR. It has anticonvulsant effects.[1]

AP-7 functions specifically as a NMDA recognition site blocker, in contrast with 7-chlorokynurenate, which acts as a glycine site modulation blocker.[2]

Animal studies

AP-7 injected directly into the dorsal periaqueductal grey (DPAG) of rats produced an anxiolytic effect, whereas direct injection outside of the DPAG did not elicit anxiolytic effects, suggesting that the anxiolytic effect of NMDA antagonists in rats may depend on their action in the DPAG.[3]

The DPAG of the brain is thought to deal with fear-like defensive behavior via NMDA and glycine B receptors.[4] These excitatory glutamate receptors work with the inhibitory GABA receptors to achieve equilibrium in the DPAG of the brain.[5]

AP-7 has been known to cause muscle rigidity and catalepsy in rats following bilateral microinjections (0.02-0.5 nmol) into the globus pallidus and ventral-posterior portions of the caudate-putamen.[6]

The optically pure D-(−)-2-amino-7-phosphonoheptanoic acid [D-AP7], has also been examined. In groups of hypoxia-treated rats, D-AP7 enhanced motility, exhibited anxiogenic-like effect and impaired consolidation in passive avoidance. Both AP-7 and D-AP7 function as potent, specific antagonists of the NMDA receptor.[7]

See also

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "Citation/CS1".
  2. Script error: No such module "Citation/CS1".
  3. Script error: No such module "Citation/CS1".
  4. Script error: No such module "Citation/CS1".
  5. Script error: No such module "Citation/CS1".
  6. Script error: No such module "Citation/CS1".
  7. Script error: No such module "Citation/CS1".

Script error: No such module "Check for unknown parameters".

Template:Ionotropic glutamate receptor modulators